Analytical Data
-
Gene name
PLK3 Polo Box Domain
- Application
-
Alternative Names
CNK; FNK; PRK
-
Species
Human
-
Source
E. coli
-
Tag
C-6*His;N-MBP
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9H4B4
-
Expression Region
T335-A646
-
Protein Length
Partial
-
Molecular Weight
75 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The Polo-like kinase 3 (PLK3) is a member of the Polo-like kinase family, which is known for its critical role in regulating cell cycle progression and various cellular processes. The Polo Box Domain (PBD) of PLK3 is particularly interesting, as it is responsible for binding to specific phosphorylated substrates and facilitating their subsequent phosphorylation by the kinase. Understanding the structure and function of PLK3 and its PBD has significant implications for cancer research, as aberrant expression or activity of PLK3 is linked to tumorigenesis and progression. Researchers are increasingly focused on characterizing the PBD to elucidate its role in substrate recognition and specificity. Recombination technology enables the production of PLK3 PBD as a recombinant protein, allowing scientists to study its interactions in vitro. This research can lead to insights into how PLK3 contributes to cellular signaling pathways and may uncover new therapeutic targets for cancer treatment. Additionally, investigating the PBD may help in designing small molecules that can modulate PLK3 activity, providing novel avenues for intervention in cancers where PLK3 is dysregulated. The ongoing exploration of PLK3 and its Polo Box Domain thus represents a promising frontier in the pursuit of targeted cancer therapies and a deeper understanding of cell cycle regulation.
